All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA2102940" target="_blank" >RIV/61988987:17110/20:A2102940 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/20:00116026 RIV/65269705:_____/20:00072665 RIV/00843989:_____/20:E0108389 RIV/00064203:_____/20:10412680

  • Result on the web

    <a href="https://watermark.silverchair.com/bloodbld2019000998.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA8UwggPBBgkqhkiG9w0BBwagggOyMIIDrgIBADCCA6cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZD0RPuAbrKSWgwAdAgEQgIIDeOb4wxLbO_zM6MIH9Z5f3tpX6pzgMkAtmd1" target="_blank" >https://watermark.silverchair.com/bloodbld2019000998.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA8UwggPBBgkqhkiG9w0BBwagggOyMIIDrgIBADCCA6cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZD0RPuAbrKSWgwAdAgEQgIIDeOb4wxLbO_zM6MIH9Z5f3tpX6pzgMkAtmd1</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1182/blood.2019000998" target="_blank" >10.1182/blood.2019000998</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

  • Original language description

    This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for ‡3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved. Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 months. Overall, 203 children received dabigatran, with median exposure being 36.3 weeks (range, 0-57 weeks); 171 of 203 (84.2%) and 32 of 203 (15.8%) took capsules and pellets, respectively. Overall, 2 of 203 children (1.0%) experienced on-treatment VTE recurrence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinically relevant nonmajor bleeding events, and 37 (18.2%) minor bleeding events. There were no on-treatment deaths. On-treatment postthrombotic syndrome was reported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s). This trial was registered at www.clinicaltrials.gov as #NCT02197416. (Blood. 2020;135(7):491-504) © 2020 by The American Society of Hematology

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood

  • ISSN

    0006-4971

  • e-ISSN

  • Volume of the periodical

    135

  • Issue of the periodical within the volume

    7

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    14

  • Pages from-to

    491-504

  • UT code for WoS article

    000522643100005

  • EID of the result in the Scopus database